Document Classification

Section Type: METHODS

Text: We evaluated the response rate safety of new platinum analogue regimens, randomizing 147 patients with nonoperable IIIB/IV NSCLC to (i) carboplatin (area under the curve = 5 mg min/ml) on day 1 plus gemcitabine (GEM) (1000 mg/m (2)) on days 1 and 8 for six cycles ; (ii) same regimen for three cycles followed by docetaxel (Taxotere) (40 mg/m (2)) on days 1 and 8 plus GEM (1250 mg/m (2)) on days 1 and 8 for three cycles ; (iii) oxaliplatin (130 mg/m (2)) on day 1 plus GEM (1250 mg/m (2)) on days 1 and 8 for six cycles.